Terminated PHASE2 INTERVENTIONAL 1-arm NCT01941550

Neoadjuvant Chemotherapy With Cabazitaxel (CLUBNET)

Neoadjuvant Chemotherapy With Cabazitaxel in High Risk Prostate Cancer Patients Prior to Radical Prostatectomy

Sponsor: RWTH Aachen University

Updated 5 times since 2017 Last updated: Sep 12, 2016 Started: Jul 31, 2013 Primary completion: Jan 31, 2016 Completion: Jan 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Investigator left the site. Site closed.

Other terminated trials from RWTH Aachen University

See all terminations from RWTH Aachen University

A PHASE2 clinical study on High-Risk Cancer, this trial is terminated or withdrawn. The trial is conducted by RWTH Aachen University and has accumulated 5 data snapshots since 2013. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE2
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE2
Jan 2017 — Jun 2018 [monthly]

Terminated PHASE2

First recorded

Jul 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

RWTH Aachen University

Data source: RWTH Aachen University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Aachen, Germany